Primitive neuroectodermal tumours (PNETs) are the largest group of malignant brain tumours in children.

They can arise from the brain's cerebellum or, more rarely, from tissue located throughout the central nervous system (CNS).

Little is known about how CNS-PNETs develop, although these tumours are more aggressive than other PNETs and have an overall survival rate of only about 20 percent.

In a new study, researchers for the first time have identified a possible target for a new CNS-PNET therapy.

Rodney Stewart will present this research during the Cancer symposium as part of The Allied Genetics Conference.

The study was carried out by researchers from the University of Utah Huntsman Cancer Institute in Salt Lake City and the University of Toronto Hospital for Sick Children in Ontario, Canada.

Using zebrafish, they developed the first animal model for the oligoneural subtype of CNS-PNET.

A novel drug screening platform for zebrafish brain tumours was then designed to identify drugs that could eliminate brain tumours without affecting development of the normal brain.

These studies showed that inhibiting the activity of the signalling protein MEK was essential for these tumours to grow.

As these compounds are already approved for clinical trails in MEK activity could offer a new therapy option for children with these devastating

Source: The Allied Genetics Conference